

SUPPLEMENTARY TABLES

Supplementary Table 1. siRNA pools used in this study.

NRF2 siRNA pool [1]:

NFE2L2-1 mGmAUUCUGACUCCGGCAUUUTT AmAAUGCCGGAGUCAGAAUCTT
NFE2L2-2 mCmACUACUUGGCCUCAGUGATT UmCACUGAGGCCAAGUAGUGTT
NFE2L2-3 mCmUCACAAGAGAUGAACUUATT UmAAGUUCAUCUCUUGUGAGTT
NFE2L2-4 mGmAGAUGAACUUAGGGCAAATT UmUUGCCCUAAGUUCAUCUCTT
NFE2L2-5 mGmCUCAUACUUUAUAAGUAATT UmUACUUAUAAAGUAUGAGCTT
NFE2L2-6 mGmAGACUACCAUGGUUCCAATT UmUGGAACCAUGGUAGUCUCTT
NFE2L2-7 mCmUGUUGAUUUAGACGGUAUTT AmUACCGUCUAAAUCAACAGTT
NFE2L2-8 mGmCCCUCACCGUCUACUUUATT UmAAAGUAGCAGGUGAGGGCTT
NFE2L2-9 mCmCAUUCACUCUCUGAACUUTT AmAGUUCAGAGAGUGAAUGGTT
NFE2L2-10 mGmUCACUUGUUCUGAUUAUUTT AmAUAUCAGGAACAAGUGACTT

KEAP1 siRNA pool:

KEAP1-1 mCmGAAUGACAUCGGGCCGGATT UmCCGGCCCCGAUGUCAUUCGTT
KEAP1-2 mGmUGUUACGACCCAGAUACATT UmGUAUCUGGGUCGUAACACTT
KEAP1-3 mCmCUUAAUUCAGCUGAGUGUTT AmCACUCAGCUGAAUUAAGGTT
KEAP1-4 mCmAGAUUGGCUGUGUGGAGUTT AmCUCCACACAGCCAAUCUGTT
KEAP1-5 mGmCUAUGAUGGUCACACGUUTT AmACGUGUGACCAUCAUAGCTT
KEAP1-6 mGmGUUCUACGUCCAGGCGCUTT AmGCGCCUGGACGUAGAACCTT
KEAP1-7 mGmCAUCAACUGGGUCAAGUATT UmACUUGACCCAGUUGAUGCTT
KEAP1-8 mGmGGACAAACCGCCUUAUUTT AmAUUAAGGCGGUUUGUCCCTT
KEAP1-9 mCmGCCUAAUUCAGCUGAGUTT AmCUCAGCUGAAUUAAGGCGTT
KEAP1-10 mCmGAAUGAUCACAGCAAUGATT UmCAUUGCUGUGAUCAUUCGTT

GLUT1 siRNAs [2]

Sense 5'- CCUCUUUGUUAUUCGCUUU -3', Antisense: 5'- AAAGCGAUUAACAAAGAGG -3'

Supplementary Table 2. RT-qPCR primers for Nrf2 target genes.

NRF2	5'-CAGCGACGGAAAGAGTATGA-3'	5'-TGGGCAACCTGGGAGTAG-3'
Actin	5'-CTGGAACGGTGAAGGTGACA-3'	5'-AAGGGACTTCCTGTAACAATGCA-3'
GCLC	5'-CCCTCGCTTCAGTACCTTAAC-3'	5'-GACAGCAATTGCCCATTTCCA-3'
GCLM	5'-AGTGGGCACAGGTAACCA-3'	5'-CTCGTGCGCTTGAATGTCAG-3'
HO-1	5'-CTGCTCAACATCCAGCTCTTTG-3'	5'-AGTGTAAGGACCCATCGGAGA-3'
NQO1	5'-CAAAGGACCTTCCGGAGTAA-3'	5'-ACTTGGAAAGCCACAGAAATGC-3'

Supplementary Table 3. Clinical information of patients in immunohistochemistry experiment in Figure 1A–1B.

Patent number	Age	Gender	Cancer stage	Surgery	Cisplatin treatment
1	78	M	IIIA	N	Y
2	62	M	IIIB	Y	Y
3	83	M	IIIB	N	Y
4	74	M	II	N	Y
5	66	F	IIIA	N	Y
6	80	F	IIIA	N	Y
7	76	F	IIIB	Y	Y
8	47	F	IIIA	Y	Y
9	69	M	IVA	N	N
10	77	M	IVA	N	N
11	65	M	IIIB	Y	N
12	74	M	IVA	N	N
13	83	F	IIIB	N	N
14	73	F	IVA	M	N
15	56	F	IVA	N	N
16	75	F	IIIB	N	N

SUPPLEMENTARY REFERENCES

1. Fourtounis J, Wang IM, Mathieu MC, Claveau D, Loo T, Jackson AL, Peters MA, Therien AG, Boie Y, Crackower MA. Gene expression profiling following NRF2 and KEAP1 siRNA knockdown in human lung fibroblasts identifies CCL11/Eotaxin-1 as a novel NRF2 regulated gene. *Respir Res.* 2012; 13:92.
<https://doi.org/10.1186/1465-9921-13-92>
PMID:[23061798](https://pubmed.ncbi.nlm.nih.gov/23061798/)
2. Ida-Yonemochi H, Nakatomi M, Harada H, Takata H, Baba O, Ohshima H. Glucose uptake mediated by glucose transporter 1 is essential for early tooth morphogenesis and size determination of murine molars. *Dev Biol.* 2012; 363:52–61.
<https://doi.org/10.1016/j.ydbio.2011.12.020>
PMID:[22226978](https://pubmed.ncbi.nlm.nih.gov/22226978/)